IRVINE, Calif. / Oct 09, 2025 / Business Wire / Masimo (NASDAQ: MASI) today announced it will host a meeting with the analyst and investor community at 9:00am PT on Wednesday, December 3, 2025.
Presentations will be led by select members of the Executive Leadership Team and will cover an overview of the company’s business, market opportunities, innovation pipeline, commercial growth strategy, and long-term financial outlook.
The company invites investors to join the event via live webcast, which will be available on the Investor Relations section of its website at https://investor.masimo.com/ under “Events and Presentations” or directly by visiting the following link: Masimo Investor Day webcast. A replay of the webcast and the related slide presentations will be available on the company’s website following the event. In-person attendance is by invitation only and registration will be required.
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, automation and connectivity solutions. Our mission is for Masimo innovations to empower clinicians to transform patient care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com.
Last Trade: | US$146.28 |
Daily Change: | -4.25 -2.82 |
Daily Volume: | 153,415 |
Market Cap: | US$7.950B |
October 07, 2025 September 17, 2025 September 11, 2025 August 28, 2025 August 19, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load